文献速递妇产影像儿科影像心血管USMR

胎儿单心室心脏病中持续低剂量母体补充氧气的安全性与可行性初步研究

Safety and feasibility pilot study of continuous low-dose maternal supplemental oxygen in fetal single ventricle heart disease.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-01-01

单中心、开放标签、1期初步试验纳入25例胎儿单心室生理孕妇,自妊娠后半期至分娩自我给予持续低剂量母体补充氧气(每日中位16.1小时,中位63天,累计中位1029小时),仅见可缓解的鼻部并发症,未见动脉导管提前闭合或意外胎死;与217例标准照护队列比较,未增加胎儿脑氧输送或改善早期神经发育结局。

要点

  • 持续低剂量母体补充氧气在胎儿单心室生理孕妇中安全且耐受良好,仅见鼻部并发症。
  • 未观察到动脉导管提前闭合或意外胎死。
  • 与标准照护相比,未增加胎儿脑氧输送或改善18月龄神经发育结局。

核心结论

  • 低剂量母体补充氧气治疗在胎儿单心室生理孕妇中安全且耐受良好,但方案未增加胎儿脑氧输送,也未改善早期神经或神经发育结局。

研究设计与样本

  • 单中心、开放标签、1期安全性与可行性初步临床试验,纳入25例胎儿单心室生理孕妇,自妊娠后半期至分娩每日最多24小时自我给予医用级氧气浓缩器持续母体补充氧气,主要目标为评估安全性与可行性。

局限性

  • 本文为初步1期临床试验,样本量为25例。
  • 原文结论指出方案未增加胎儿脑氧输送或改善早期神经或神经发育结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Fetuses with single ventricle physiology (SVP) exhibit reductions in fetal cerebral oxygenation, with associated delays in fetal brain growth and neurodevelopmental outcomes. Maternal supplemental oxygen (MSO) has been proposed to improve fetal brain growth, but current evidence on dosing, candidacy and outcomes is limited. In this pilot study, we evaluated the safety and feasibility of continuous low-dose MSO in the setting of SVP.

METHODS: This single-center, open-label, pilot phase-1 safety and feasibility clinical trial included 25 pregnant individuals with a diagnosis of fetal SVP. Participants self-administered continuous MSO using medical-grade oxygen concentrators for up to 24 h per day from the second half of gestation until delivery. The primary aim was the evaluation of the safety profile and feasibility of MSO. A secondary preliminary analysis was performed to assess the impact of MSO on the fetal circulation using echocardiography and late-gestation cardiovascular magnetic resonance imaging. Early outcomes were assessed, including perinatal growth and preoperative brain injury, and neurodevelopmental outcomes were assessed at 18 months using the Bayley Scales of Infant and Toddler Development 3rd edition, and compared with those of a contemporary fetal SVP cohort (n = 217) that received the normal standard of care (SOC).

RESULTS: Among the 25 participants, the median maternal age at conception was 35 years, and fetal SVP diagnoses included 16 with right ventricle dominant, eight with left ventricle dominant and one with indeterminate ventricular morphology. Participants started the trial at approximately 29 + 2 weeks' gestation and self-administered MSO for a median of 16.1 h per day for 63 days, accumulating a median of 1029 h of oxygen intake from enrolment until delivery. The only treatment-associated adverse events were nasal complications that were resolved typically by attaching a humidifier unit to the oxygen concentrator. No premature closure of the ductus arteriosus or unexpected fetal demise was observed. In the secondary analysis, MSO was not associated with any changes in fetal growth, middle cerebral artery pulsatility index, cerebroplacental ratio or head-circumference-to-abdominal-circumference ratio Z-scores over gestation compared with SOC. Although MSO was associated with changes in umbilical artery pulsatility index Z-score over the study period compared with SOC (P = 0.02), this was probably due to initial baseline differences in placental resistance. At late-gestation cardiovascular magnetic resonance imaging, MSO was not associated with an increase in fetal cerebral oxygen delivery. Similarly, no differences were observed in neonatal outcomes, including preoperative brain weight Z-score and brain injury, mortality by 18 months of age and neurodevelopmental outcomes at 18 months of age.

CONCLUSIONS: This pilot phase-1 clinical trial indicates that low-dose MSO therapy is safe and well tolerated in pregnancies diagnosed with fetal SVP. However, our protocol was not associated with an increase in fetal cerebral oxygen delivery or improvements in early neurological or neurodevelopmental outcomes. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lee FT, Sun L, Szabo A, et al. Safety and feasibility pilot study of continuous low-dose maternal supplemental oxygen in fetal single ventricle heart disease. Ultrasound Obstet Gynecol. 2024. PMID: 38629477. doi:10.1002/uog.27657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。